ADPKD Clinical Trial
Official title:
Chart Review/PKD Genotyping
This is a retrospective analysis to include demographic, clinical, biochemical, and genetic data that will further explore the natural history of ADPKD and assess the factors that are likely to be associated with the progression of disease and the incidence of complications including progressive chronic kidney disease, cardiovascular disease, and cerebrovascular disease.
To explore questions regarding the natural history of PKD, as well as other, unforeseen issues, a comprehensive database of demographic, clinical, biochemical, and genetic data is required. This descriptive retrospective study can serve as a source of information regarding either the entire ADPKD population, or subsets of patients with specifically targeted characteristics. This will inform future prospective studies that will be designed to address issues regarding the natural history and complications of ADPKD. The goal of this project is to collect data from a large population of patients with PKD. Based upon the estimated prevalence of PKD (1:500 and 1:1000 live births), it is estimated that there may be 10,000 PKD patients in the New York City area. This sample size far exceeds any database established thus far. As many as 40% of affected PKD patients are reportedly unaware of a family history of this disease, in part because many patients may go undiagnosed until they present with a medical complication (e.g., hypertension, kidney failure). Furthermore, this initiative will provide an opportunity to compare data from racially diverse populations. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
| Completed |
NCT02776241 -
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
| Terminated |
NCT04152837 -
Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03717883 -
ADPKD Alterations in Hepatic Transporter Function
|
||
| Recruiting |
NCT05014178 -
Kidney Sodium Functional Imaging
|
||
| Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
| Terminated |
NCT04064346 -
Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT03203642 -
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
|
Phase 2 | |
| Recruiting |
NCT04338048 -
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study
|
||
| Not yet recruiting |
NCT06100133 -
Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?
|
Phase 2 | |
| Completed |
NCT01632605 -
The Vienna RAP Pilot Study
|
N/A | |
| Terminated |
NCT03918447 -
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON
|
Phase 3 | |
| Recruiting |
NCT06416761 -
Genetics in the Progression of Nephropathies
|
||
| Not yet recruiting |
NCT05373264 -
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
|
Phase 3 | |
| Recruiting |
NCT06085807 -
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
|
||
| Completed |
NCT01853553 -
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
| Completed |
NCT04472624 -
Short Term Induction of Ketosis in PKD
|
N/A | |
| Not yet recruiting |
NCT03764605 -
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
| Completed |
NCT04680780 -
Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
N/A | |
| Active, not recruiting |
NCT03273413 -
Statin Therapy in Patients With Early Stage ADPKD
|
Phase 4 |